Overview

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
the investigators will conduct a phase II trial to evaluate the efficacy and toxicity of Sunitinib in patients with recurrent SCLC.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Collaborator:
Pfizer
Treatments:
Sunitinib